Cold Agglutinin Disease Market Forecast 2034: FDA Approvals, Medication, Clinical Trials, Revenue, Statistics, Therapies, Companies

Cold Agglutinin Disease Companies in the market include Apellis Pharmaceuticals, Novartis, Incyte corporation, Sanofi, Alexion Pharmaceuticals, Novartis, and others.

Cold Agglutinin Disease drugs market remains relatively niche but is steadily evolving with the introduction of targeted therapies and a growing understanding of disease biology. In 2023, the CAD market in the United States was valued at approximately USD 95 million, contributing significantly to the overall market size of around USD 190 million across the seven major markets (7MM). The US dominated the global landscape, followed by Japan, while within Europe, Germany led the EU4 and UK markets with nearly USD 18 million.

CAD is a rare autoimmune hemolytic disorder in which red blood cells are prematurely destroyed, leading to symptoms such as anemia, fatigue, shortness of breath, jaundice, and dark urine. The condition primarily affects individuals between 40 and 80 years of age and shows a higher prevalence in females. In 2023, about 13,000 cases were reported across the 7MM, with nearly 60% of cases occurring in women and the majority (around 90%) classified as primary CAD in the US.

Treatment strategies depend on disease severity and include corticosteroids, immunosuppressive agents, and biologics such as rituximab-based therapies. The approval of ENJAYMO, a first-in-class complement C1s inhibitor, has significantly transformed the treatment landscape, particularly for severe cases. Meanwhile, emerging therapies like iptacopan, pegcetacoplan, SAR445088, and INCB050465 are expected to further drive innovation and market growth.

DelveInsight’s “Cold Agglutinin Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Cold Agglutinin Disease, historical and forecasted epidemiology as well as the Cold Agglutinin Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Cold Agglutinin Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Cold Agglutinin Disease market size from 2020 to 2034, segmented by seven major markets. The Report also covers Cold Agglutinin Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Cold Agglutinin Disease market.

To Know in detail about the Cold Agglutinin Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cold Agglutinin Disease Market Forecast

Some of the key facts of the Cold Agglutinin Disease Market Report:

• The Cold Agglutinin Disease market size was valued ~USD 190 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In March 2026, Gliknik Inc. announced A Phase 1, Double-blind, Placebo-controlled, Single Ascending Intravenous and Subcutaneous Injection Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Male and Female Subjects and an Open-label Evaluation of Safety, Tolerability, Pharmacokinetics, and Pilot Efficacy Biomarkers in Subjects With Cold Agglutinin Disease
• In November 2025, RECORDATI GROUP announced a multinational, multi-center, observational, prospective, longitudinal disease registry designed to collect data on participants with cold agglutinin disease (CAD) or cold agglutinin syndrome (CAS). Among them, a minimum of 30 patients with CAD treated with sutimlimab are expected to take part in the sutimlimab cohort study. Patients with CAD who have been enrolled in previous sutimlimab clinical trials (e.g., BIVV009-01/LTS16214 [NCT02502903,CAD patients], BIVV009-03/EFC16215 [NCT03347396], and BIVV009-04/EFC16216 [NCT03347422]) and who either completed or discontinued the corresponding clinical trial are eligible to participate in the registry.
• In May 2025, Riliprubart (SAR445088), an experimental therapy being explored as a potential follow-up to Enjaymo (sutimlimab-jome) for treating cold agglutinin disease (CAD), may maintain effective drug levels with a fixed dose administered once every three months. This conclusion comes from a study that applied modeling techniques to existing clinical trial data to determine an optimal dosing schedule. The proposed regimen was subsequently validated in a Phase 1 clinical trial involving nine CAD patients.
• In November 2024, Annexon Biosciences announced that results from its ongoing proof-of-concept clinical trial evaluating ANX1502, a novel treatment for cold agglutinin disease (CAD), are now anticipated in early 2025. The study is assessing a newly developed tablet formulation of the oral therapy in individuals diagnosed with CAD.
• In 2023, Germany held the largest share of the CAD market within the EU4 and the UK, totaling approximately USD 18 million.
• In January 2024, In a Phase 1 clinical trial, Annexon Biosciences' experimental oral therapy, ANX1502, designed for autoimmune conditions like cold agglutinin disease (CAD), achieved the targeted blood levels when administered twice daily to healthy volunteers. ANX1502, delivered as a liquid suspension, was well-received with no significant adverse effects reported. The pharmacokinetics of ANX1502, detailing its distribution, metabolism, and elimination from the body, also indicated the feasibility of implementing a twice-daily dosing regimen for future proof-of-concept studies.
• In 2023, there were approximately 5,500 prevalent cases of CAD in the United States.
• In 2023, about 90% of CAD cases in the US were identified as type-specific primary cases, with the remaining 10% classified as secondary CAD.
• Within the EU4 and the UK, Germany had the highest number of prevalent CAD cases.
• In 2023, there were around 1,800 cases of CAD in males and approximately 2,660 cases in females in the US.
• Key Cold Agglutinin Disease Companies: Apellis Pharmaceuticals, Novartis, Incyte corporation, Sanofi, Alexion Pharmaceuticals, Novartis, and others
• Key Cold Agglutinin Disease Therapies: Pegcetacoplan, Iptacopan, Parsaclisib, SAR445088, Eculizumab, sutimlimab (BIVV009, Iptacopan, and others
• The Cold Agglutinin Disease epidemiology based on gender analyzed that Cold Agglutinin Disease frequency is usually more in females than in males
• The Cold Agglutinin Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cold Agglutinin Disease pipeline products will significantly revolutionize the Cold Agglutinin Disease market dynamics

Cold Agglutinin Disease Overview

Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia characterized by the presence of cold-reacting autoantibodies, known as cold agglutinins, in the blood. These autoantibodies target and bind to red blood cells at temperatures lower than normal body temperature, leading to their premature destruction (hemolysis) when exposed to cold environments, such as cold weather or refrigeration.

Get a Free sample for the Cold Agglutinin Disease Market Report: https://www.delveinsight.com/report-store/cold-agglutinin-disease-cad-market

Cold Agglutinin Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Cold Agglutinin Disease Epidemiology Segmentation:

The Cold Agglutinin Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Cold Agglutinin Disease
• Prevalent Cases of Cold Agglutinin Disease by severity
• Gender-specific Prevalence of Cold Agglutinin Disease
• Diagnosed Cases of Episodic and Chronic Cold Agglutinin Disease

Download the report to understand which factors are driving Cold Agglutinin Disease epidemiology trends @ Cold Agglutinin Disease Epidemiology Forecast

Cold Agglutinin Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cold Agglutinin Disease market or expected to get launched during the study period. The analysis covers Cold Agglutinin Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cold Agglutinin Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cold Agglutinin Disease Therapies and Key Companies

• Pegcetacoplan: Apellis Pharmaceuticals
• Iptacopan: Novartis
• Parsaclisib: Incyte corporation
• SAR445088: Sanofi
• Eculizumab: Alexion Pharmaceuticals
• sutimlimab (BIVV009): Sanofi
• Iptacopan: Novartis

Discover more about therapies set to grab major Cold Agglutinin Disease market share @ Cold Agglutinin Disease Treatment Market

Cold Agglutinin Disease Market Strengths

• Several organizations and companies like Cold agglutinin disease foundation and Sanofi Genzyme are raising awareness about the disease which can lead to increased patient pool.

Cold Agglutinin Disease Market Opportunities

• Mild anemic patients because of CAD don't have such a pharmaceutical treatment option, so there is an unsaid need for the drugs in mild anemic patients.

Scope of the Cold Agglutinin Disease Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Cold Agglutinin Disease Companies: Apellis Pharmaceuticals, Novartis, Incyte corporation, Sanofi, Alexion Pharmaceuticals, Novartis, and others
• Key Cold Agglutinin Disease Therapies: Pegcetacoplan, Iptacopan, Parsaclisib, SAR445088, Eculizumab, sutimlimab (BIVV009, Iptacopan, and others
• Cold Agglutinin Disease Therapeutic Assessment: Cold Agglutinin Disease current marketed and Cold Agglutinin Disease emerging therapies
• Cold Agglutinin Disease Market Dynamics: Cold Agglutinin Disease market drivers and Cold Agglutinin Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Cold Agglutinin Disease Unmet Needs, KOL’s views, Analyst’s views, Cold Agglutinin Disease Market Access and Reimbursement

To know more about Cold Agglutinin Disease companies working in the treatment market, visit @ Cold Agglutinin Disease Clinical Trials and Therapeutic Assessment

Table of Contents

1. Cold Agglutinin Disease Market Report Introduction

2. Executive Summary for Cold Agglutinin Disease

3. SWOT analysis of Cold Agglutinin Disease

4. Cold Agglutinin Disease Patient Share (%) Overview at a Glance

5. Cold Agglutinin Disease Market Overview at a Glance

6. Cold Agglutinin Disease Disease Background and Overview

7. Cold Agglutinin Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Cold Agglutinin Disease

9. Cold Agglutinin Disease Current Treatment and Medical Practices

10. Cold Agglutinin Disease Unmet Needs

11. Cold Agglutinin Disease Emerging Therapies

12. Cold Agglutinin Disease Market Outlook

13. Country-Wise Cold Agglutinin Disease Market Analysis (2020–2034)

14. Cold Agglutinin Disease Market Access and Reimbursement of Therapies

15. Cold Agglutinin Disease Market Drivers

16. Cold Agglutinin Disease Market Barriers

17. Cold Agglutinin Disease Appendix

18. Cold Agglutinin Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight